Stockholders' Deficiency	3 Months Ended
Mar. 31, 2018
Equity [Abstract]
Stockholders' Deficiency	6. STOCKHOLDERS’ DEFICIENCY On January 15, 2018, the following events occurred to effect a change in control of the Company: The Company cancelled an aggregate of 19,500,000 shares of the then 20,000,000 shares of common stock outstanding. The then officers and directors of the Company, James Cassidy and James McKillop, resigned from the offices of President and director and Vice President and director respectively, held by them. Keewon Ra was named the sole director of the Company and was named its Chief Executive Officer, Secretary and Chief Financial Officer. On January 16, 2018, the Company issued 10,180,000 shares of its common stock to 16 shareholders at par for $1,018 and issued 10,000,000 shares of its Series A Preferred stock at par for $1,000 to Jeong Chan Ra, the father of the sole officer and director of the Company.

Stockholders' Deficiency

3 Months Ended

Mar. 31, 2018

6. STOCKHOLDERS’ DEFICIENCY

On January 15, 2018, the following events occurred to effect a change in control of the Company:

The Company cancelled an aggregate of 19,500,000 shares of the then 20,000,000 shares of common stock outstanding. The then officers and directors of the Company, James Cassidy and James McKillop, resigned from the offices of President and director and Vice President and director respectively, held by them. Keewon Ra was named the sole director of the Company and was named its Chief Executive Officer, Secretary and Chief Financial Officer.

On January 16, 2018, the Company issued 10,180,000 shares of its common stock to 16 shareholders at par for $1,018 and issued 10,000,000 shares of its Series A Preferred stock at par for $1,000 to Jeong Chan Ra, the father of the sole officer and director of the Company.

Biostar Angel Stem Cell Corp 10-Q